Progress: Molecure's 2023 milestones and what lies ahead

Molecure S.A., a leading biotechnology company focused on drug discovery and development, has unveiled its annual report for 2023 at the start of the new financial year.

Related Keywords

United Kingdom ,Marcin Szumowski ,Inhibitor Program ,Drug Administration ,Regulatory Agency ,United Kingdom Medicines ,Markets Amp Regulations ,Drug Delivery ,Ingredients ,Clinical Development ,Atient Centricity ,Linical Evolution ,Pis Active Pharmaceutical Ingredients ,Regulations ,Hasei Ii ,Rna ,Small Molecule Drugs ,Research ,Clinical Trials ,